Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Setting sights on the drugs of the future

29.03.2007
Researchers at The University of Nottingham have joined forces with one of the world’s leading pharmaceutical companies, AstraZeneca, to single out potential medicines of the future.

In a unique collaboration between academia and the pharmaceutical industry, teams of experts from both sides gathered together at an ‘ideas generation’ event, designed specifically to identify new areas for research into treatments that can be targeted at cancer, arthritis, cardio-pulmonary disease and other conditions.

The partnership underlines the significance of the EPSRC (Engineering and Physical Sciences Research Council)/AstraZeneca Doctoral Training Centre at the University, set up in 2006 as a direct collaboration with an industry partner to help develop pioneering treatments based on ‘targeted therapeutics’ — regarded as one of the significant future areas in 21st century medicine and in which The University of Nottingham is a UK leader.

The principle behind targeted therapeutics is to send medicines to the parts of the body where they are most needed, at the right time and in the right dose. In this way, diseased sites can be attacked directly, while healthy cells are bypassed, increasing the efficacy of the treatment and reducing side effects.

The University’s £2.5 million EPSRC/AstraZeneca Doctoral Training Centre is training 25 of the UK’s most promising pharmacy PhD students over the next five years in targeted therapeutics. Some of these PhD projects will now focus on ideas generated by the recent ‘ideas generation’ event with AstraZeneca. The ideas which came out of the day-and-a-half meeting, focused on a range of topics including chemistry of new drug delivery systems, biophysical analysis of dosage forms, process analytical technologies and cellular transport of drugs and drug carriers.

Dr Amanda Zeffman, Project Officer, said that the event was one of the first such meetings to take place between academics and scientists from industry.

Dr Zeffman said: “The intention was to generate ideas for PhD projects within the Doctoral Training Centre as well as to encourage general discussion in a relaxed environment, and it was extremely successful.

“By bringing together academics from the Schools of Chemistry, Maths, Computer Science and Physics, with PARD (Pharmaceutical and Analytical Research and Development) and discovery teams from AstraZeneca, we are able to combine the best of academia and industry to establish mutual interests and get a unique perspective on key areas in targeted therapeutics.”

EPSRC's first Doctoral Training Centres were launched in 2002 by EPSRC's Life Sciences Interface Programme. They offer a multi-disciplinary approach to postgraduate training bridging the gap between the medical, biological and physical sciences.

In the Nottingham Doctoral Training Centre, during the initial year of the four-year PhD, students will receive a thorough grounding in pharmaceutical sciences and will spend the first six months completing three, eight-week training projects, of which one is based within AstraZeneca. Each rotation will be in a different research group to enable students to benefit fully from the breadth of research being conducted in the School and by AstraZeneca.

The remaining three years of their time at the centre will be spent working on research projects centred on the theme of targeted therapeutics and drawing on everything from pharmaceutical nanotechnology and biopharmaceuticals to advanced physical, mathematical and life sciences.

AstraZeneca is a global leader in six major areas of healthcare — cardiovascular, gastrointestinal, infection, neuroscience, oncology and respiratory and inflammation — and the partnership with the company will provide a key commercial and clinical focus for the centre. It will improve the prospects of the students gaining jobs within the pharmaceutical industry after completing their training.

Emma Thorne | alfa
Further information:
http://www.nottingham.ac.uk/public-affairs/press-releases/index.phtml?menu=pressreleases&code=SETT-45/07&create_date=21-mar-2007

Further reports about: AstraZeneca Doctoral PhD Pharmaceutical Therapeutics targeted

More articles from Life Sciences:

nachricht Nerves control the body’s bacterial community
26.09.2017 | Christian-Albrechts-Universität zu Kiel

nachricht Ageless ears? Elderly barn owls do not become hard of hearing
26.09.2017 | Carl von Ossietzky-Universität Oldenburg

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The fastest light-driven current source

Controlling electronic current is essential to modern electronics, as data and signals are transferred by streams of electrons which are controlled at high speed. Demands on transmission speeds are also increasing as technology develops. Scientists from the Chair of Laser Physics and the Chair of Applied Physics at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have succeeded in switching on a current with a desired direction in graphene using a single laser pulse within a femtosecond ¬¬ – a femtosecond corresponds to the millionth part of a billionth of a second. This is more than a thousand times faster compared to the most efficient transistors today.

Graphene is up to the job

Im Focus: LaserTAB: More efficient and precise contacts thanks to human-robot collaboration

At the productronica trade fair in Munich this November, the Fraunhofer Institute for Laser Technology ILT will be presenting Laser-Based Tape-Automated Bonding, LaserTAB for short. The experts from Aachen will be demonstrating how new battery cells and power electronics can be micro-welded more efficiently and precisely than ever before thanks to new optics and robot support.

Fraunhofer ILT from Aachen relies on a clever combination of robotics and a laser scanner with new optics as well as process monitoring, which it has developed...

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Nerves control the body’s bacterial community

26.09.2017 | Life Sciences

Four elements make 2-D optical platform

26.09.2017 | Physics and Astronomy

Goodbye, login. Hello, heart scan

26.09.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>